SGHT - NASDAQ
Sight Sciences, Inc.
$4.55
+4.8%Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
At a Glance
Live SnapshotSight Sciences, Inc. Management Team
Mr. Matthew W. Link
Chief Commercial Officer
Compensation
$157,614
Ms. Alison Perry Bauerlein
Chief Financial Officer, Principal Financial & Accounting Officer and Treasurer
Compensation
$888,543
Mr. Jeremy B. Hayden J.D.
Chief Legal Officer & Corporate Secretary
Compensation
$829,652
Dr. Reay H. Brown M.D.
Chief Medical Officer
Dr. David Badawi M.D.
Co-Founder, Chief Technology Officer & Director
Mr. Paul Badawi
Co-Founder, President, Chief Executive Officer & Director
Compensation
$1,352,179
Mr. Brenton Taylor
Executive Vice President of Operations
Dr. Manohar K. Raheja Ph.D.
Executive Vice President of Research & Development
Mr. Steve R. Tamayo Jr.
Vice President and Chief Ethics & Compliance Officer
Mr. Jim Rodberg
Vice President of Finance & Corporate Controller
Sight Sciences, Inc. Insider Positioning
During the last 12 months, insiders have purchased $498K and sold $2.23M worth of SGHT shares, resulting in $1.73M of net selling activity.
3 Months
0
0.00
99.9K
376.97K
-377K
-$377K
3-6 Months
14.0K
115.96K
120.3K
877.08K
-761K
-$761K
6-9 Months
0
0.00
125.7K
711.18K
-711K
-$711K
9-12 Months
90.5K
381.96K
102.6K
263.84K
+118K
+$118K
Top Buyers
Encrantz Staffan
Director, 10 Percent Owner:
$498K
Top Sellers
Badawi Paul
Director, 10 Percent Owner, Officer: President And Ceo
$713K
Hayden Jeremy B.
Officer: Chief Legal Officer
$635K
Bauerlein Alison
Officer: Chief Operating Officer
$457K
Badawi David
Director, Officer: Chief Technology Officer
$182K
Taylor Brenton
Officer: Evp, Operations & R&D
$119K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $1.73M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Weak buy/sell ratio. Selling significantly exceeds buying—monitor for potential fundamental concerns.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider sellers vs. 1 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
SEC Filings
SGHT - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 22, 2026 | June 04, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 23, 2025 | June 05, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 26, 2024 | June 06, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 26, 2023 | June 08, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 29, 2022 | June 08, 2022 | 2022 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.